Skip to main content

Advertisement

The actions of exogenous leucine on mTOR signalling and amino acid transporters in human myotubes

BMC Physiologyvolume 11, Article number: 10 (2011) | Download Citation

Article metrics

Abstract

Background

The branched-chain amino acid (BCAA) leucine has been identified to be a key regulator of skeletal muscle anabolism. Activation of anabolic signalling occurs via the mammalian target of rapamycin (mTOR) through an undefined mechanism. System A and L solute carriers transport essential amino acids across plasma membranes; however it remains unknown whether an exogenous supply of leucine regulates their gene expression. The aim of the present study was to investigate the effects of acute and chronic leucine stimulation of anabolic signalling and specific amino acid transporters, using cultured primary human skeletal muscle cells.

Results

Human myotubes were treated with leucine, insulin or co-treated with leucine and insulin for 30 min, 3 h or 24 h. Activation of mTOR signalling kinases were examined, together with putative nutrient sensor human vacuolar protein sorting 34 (hVps34) and gene expression of selected amino acid transporters. Phosphorylation of mTOR and p70S6K was transiently increased following leucine exposure, independently to insulin. hVps34 protein expression was also significantly increased. However, genes encoding amino acid transporters were differentially regulated by insulin and not leucine.

Conclusions

mTOR signalling is transiently activated by leucine within human myotubes independently of insulin stimulation. While this occurred in the absence of changes in gene expression of amino acid transporters, protein expression of hVps34 increased.

Background

Amino acids are essential for the regulation of cell growth and proliferation [1, 2] in two ways; by providing the substrate required for polypeptide biosynthesis, and by modulating signalling pathways responsible for protein synthesis [3–6]. Various cell models have examined the anabolic potential of the branched chain amino acid (BCAA), leucine, to stimulate skeletal muscle growth via mammalian target of rapamycin (mTOR) signalling [7, 8, 3, 9, 10]. Phosphorylation of mTOR complex 1, a rapamycin-sensitive kinase, is vital for downstream activation of phosphokinases required for translational initiation. Stimulation of mTOR by nutrients or insulin activates p70 ribosomal S6 kinase (p70S6K), a key mediator of the protein synthesis cascade [11]. Active p70S6K subsequently leads to phosphorylation of its downstream target, ribosomal protein S6 kinase (S6). This results in the translation of messenger RNA (mRNA) which encode for ribosomes and transcription factors, an essential process leading to increased cellular capacity to undergo protein synthesis [12]. Moreover, mTOR-catalysed stimulation of eukaryotic initiation factor 4E-binding protein (4E-BP1) results in its disassociation from eukaryotic initiation factor 4E (eIF4E). Subsequent binding of eIF4E to eIF4G forms the eIF4F translation initiation complex, and allows the recruitment of the 40S ribosomal subunit to the 5'-end of the mRNA to initiate protein translation [13].

Despite extensive evidence linking leucine with the activation of anabolic signalling [14–18, 7, 19–22, 10], the proximal mechanisms by which mTOR responds to intracellular levels of leucine remain elusive. To date, several intermediary 'nutrient sensing' molecules, such as those characterised in Saccharomyces cerevisiae and bacteria, have been implicated in directing amino acid signalling to mTOR [23, 24]. The ste-20 related mitogen-activated protein kinase kinase kinase kinase 3 (MAP4K3), activating proteins Rag 1-4 and class III phosphatidylinositol 3'-kinase vacuolar protein sorting 34 (Vps34) are thought to converge on signalling through mTOR in mammalian cells [25–27]. However, recent evidence from rodent models suggests that it is the activity of Vps34 which is the primary modulator of leucine-stimulated mTOR signalling in rat muscle [28]. Furthermore, it has been previously demonstrated that human vacuolar protein sorting 34 (hVps34) is required for nutrient activation of p70S6K, via mTOR signalling [29].

The intricate balance of amino acid influx and efflux in skeletal muscle is maintained by both system A and system L transport proteins, which are responsive to amino acid starvation and hormones [30–32]. Sodium coupled neutral amino acid transporter 2 (SNAT2), the predominant system A member expressed in human skeletal muscle, is reportedly regulated by both insulin and amino acid deprivation in cultured L6 myotubes [31, 33]. Additionally, leucine exposure following serum withdrawal causes an enhanced rate of uptake of N-methylamino-alpha-isobutyric acid (MeAIB), a system A substrate, by SNAT2 [34]. However, it remains unknown whether enhanced uptake by SNAT2 occurs via increased gene transcription, augmented protein synthesis of the amino acid transporter or by increased activity. Similarly, system L-type amino acid transporters (LAT) have been extensively examined for their possible role in tumour growth, and exhibit a high affinity for BCAA [35, 36]. Given the extensive evidence describing the potency of BCAA on mTOR-driven protein synthesis in skeletal muscle, no studies to date have examined the regulation of LAT transporters by amino acids, specifically BCAA. Identifying the effectiveness of leucine as a regulator of amino acid transporters within skeletal muscle will provide further insight in the role these proteins play in the control anabolic signalling.

Therefore in the present study, a human cell culture model was used to; (1) compare and contrast the effects of acute and chronic nutrient and hormonal stimulation of anabolic signalling which occurs in skeletal muscle, and (2) analyse their ability to modulate protein expression of the putative nutrient sensor, hVps34, and gene expression of selected amino acid transporters. It was hypothesised that leucine stimulated phosphorylation of mTOR-related signalling kinases would occur together with activation of hVps34 and amino acid transporter gene expression.

Results

Confirmation of a homogenous primary myotube culture

Purity of primary myotube cultures was assessed by immunocytochemical labelling of the muscle cell marker myogenin (green; Figure 1). A typical purity of 95% was achieved.

Figure 1
figure1

Cultured human primary myotubes labelled for myogenin. Primary myoblasts were grown to near confluence and induced to differentiate for 7 days. Myogenin (green) was detected by immunocytochemistry using anti-myogenin antibody followed by anti-mouse Alexa 488 secondary antibody. Scale bar = 30 μm.

Full size image

Leucine and insulin independently regulate mTOR signalling

Leucine and insulin are known activators of mTOR in human skeletal muscle tissue. Thus the ability of these stimuli to regulate the expression of phosphorylated mTOR both individually and together in human myotubes was assessed (Figure 2). Cells treated with leucine or insulin for 30 min demonstrated a significant increase in phosphorylated serine mTOR following normalisation with total mTOR (1.3-fold, P < 0.01 and 1.6-fold; P < 0.05 respectively). Protein abundance of total mTOR did not change following treatment for all timepoints examined (Additional file 1, Figure S1). No evidence of synergistic activation of mTOR with combined leucine and insulin treatment was evident. Conversely, cultures stimulated for 3 h displayed increased mTOR expression under all treatment conditions, with the greatest increase observed with insulin stimulation (2.0-fold; P < 0.001). This was found to be maintained with co-treatment of leucine and insulin (2.0-fold; P < 0.01). At 24 h the response was diminished, with only insulin-treated myotubes exhibiting significant increases in mTOR phosphorylation (1.5-fold; P < 0.01), above baseline.

Figure 2
figure2

Leucine and insulin independently regulate mTOR signalling. Primary human myotubes were untreated or incubated in the presence of leucine (Leu; 5 mM), insulin (Ins; 100 nM) or co-treated with leucine and insulin (Leu + Ins) for 30 min (A), 3 h (B) or 24 h (C). Phosphorylation levels of mTOR at Ser2448 were determined by Western blot analysis relative to total levels of mTOR. Data are presented as mean ± SEM (n = 6). *P < 0.05, **P < 0.01, ***P < 0.001 versus untreated.

Full size image

Protein abundance of putative nutrient sensing protein, hVps34, is increased in response to leucine and insulin stimulation

It has been previously suggested that the activation of anabolic signalling is mediated through the nutrient-sensing protein, hVps34. In order to investigate whether the BCAA member, leucine, enhances hVps34 protein expression, hVps34 protein expression was measured in leucine and insulin-stimulated myotubes (Figure 3). Immunoblotting revealed that acute exposure (30 min) was sufficient to significantly increase hVps34 protein abundance in cells treated with leucine alone (1.3-fold; P = 0.05) and insulin alone (1.5-fold; P < 0.05). No synergistic effect occurred following co-treatment of leucine and insulin together. Similar increases were seen following 3 h stimulation of leucine (P < 0.001) and insulin (P < 0.001) with significant increases in hVps3 abundance occurring after co-stimulation of leucine with insulin (1.5-fold; P < 0.05). hVps34 protein expression remained elevated following incubation with leucine alone (P < 0.05) and insulin alone (P < 0.05) for 24 h.

Figure 3
figure3

Leucine and insulin supply modulate the protein abundance of hVps34. Primary human myotubes were untreated or incubated in the presence of leucine (Leu; 5 mM), insulin (Ins; 100 nM or co-treated with leucine and insulin (Leu + Ins) for 30 min (A), 3 h (B) or 24 h (C). hVps34 protein abundance was determined by Western blot analysis. Data are presented as mean ± SEM (n = 6). *P < 0.05, ***P < 0.001 versus untreated.

Full size image

Leucine and insulin independently and synergistically regulate p70S6K signalling

Activation of the downstream effector, p70S6K (Figure 4), occurred in response to both leucine (2.0-fold; P < 0.05) and insulin (2.0-fold; P < 0.01). Co-treatment with leucine and insulin resulted in synergistic activation of p70S6K (2.9-fold; P < 0.01) when normalised to total p70S6K. Interestingly, stimulation of leucine alone for 3 h did not affect levels of phosphorylated p70S6K on threonine 389, whereas insulin alone did (3.3-fold; P < 0.01). Similar observations occurred when myotubes were chronically treated for 24 h with insulin (2.7-fold; P < 0.05). No activation in response to leucine was detected following 24 h treatment.

Figure 4
figure4

Effect of leucine, insulin or in combination, on the phosphorylation state of p70S6K. Primary human myotubes were untreated or incubated in the presence of leucine (Leu; 5 mM), insulin (Ins; 100 nM) or co-treated with leucine and insulin (Leu + Ins) for 30 min (A), 3 h (B) or 24 h (C). Phosphorylation levels of p70S6K at Thr389 were determined by Western blot analysis relative to total levels of p70S6K. Data are presented as mean ± SEM (n = 6). *P < 0.05, **P < 0.01, ***P < 0.001 versus untreated.

Full size image

Leucine and insulin induce translation initiation via activation of eIF4G

The effect of leucine and insulin on the activation of translation initiation was compared by measuring phosphorylation of eIF4G (Figure 5). Ser1108 phosphorylation significantly increased with 30 min insulin exposure (1.5-fold; P < 0.01) but remained unaltered upon exposure to leucine when normalised to total eIF4G. Contrastingly, exposure to leucine alone for both 3h and 24 h, and in combination with insulin, significantly stimulated signalling through eIF4G.

Figure 5
figure5

Effect of leucine, insulin or in combination, on the activation of eIF4G. Primary human myotubes were untreated or incubated in the presence of leucine (Leu; 5 mM), insulin (Ins; 100 nM) or co-treated with leucine and insulin (Leu + Ins) for 30 min (A), 3 h (B) or 24 h (C). Phosphorylation levels of eIF4G at Ser1108 were determined by Western blot analysis relative to total levels of eIF4G. Data are presented as mean ± SEM (n = 6). *P < 0.05, **P < 0.01, ***P < 0.001 versus untreated.

Full size image

Insulin but not leucine differentially regulates amino acid transporters

To assess whether members of the system A and L transporter families undergo adaptive regulation following amino acid or insulin treatment, SNAT2, LAT1, LAT4 and CD98hc gene expression was measured (Figure 6). SNAT2 and LAT1 mRNA expression was not altered by leucine or insulin. Conversely, insulin alone or in combination with leucine resulted in a significant down-regulation of LAT4 at 3 h and 24 h. Insulin stimulation for 3 h significantly up-regulated CD98hc gene expression (1.2-fold, P < 0.01), however exposure for 24 h caused a significant decrease (0.3-fold, P < 0.001). LAT4 mRNA expression was unaltered by leucine treatment.

Figure 6
figure6

Altered expressions of genes associated with amino acid transport. The mRNA expression of SNAT2 (A), LAT1 (B), LAT4 (C) and associated glycoprotein CD98hc (D) was measured in primary human myotubes incubated with and without the presence of leucine (Leu; 5 mM), insulin (Ins; 100 nM) or co-treated with leucine and insulin (Leu + Ins) for periods indicated. Expression was detected by semi-quantitative real time polymerase chain reaction (qPCR) using specific oligonucleotide primers. Values are arbitrary units normalised to the expression levels of reference gene cyclophilin presented as means the means ± SEM (n = 6). *P < 0.05, **P < 0.01, ***P < 0.001 versus untreated.

Full size image

Discussion

The aim of this study was to evaluate the anabolic effect of acute and chronic leucine and insulin stimulation in a model of human skeletal muscle. It was important to determine whether leucine could mediate mTOR-related signalling via activation of the putative regulator, hVps34, and amino acid transporters. The present work demonstrates the ability of the BCAA member, leucine, to independently stimulate mTOR signalling in an experimental model of human skeletal muscle. Although p70S6K was only transiently activated by leucine, chronic stimulation resulted in enhanced phosphorylation of the ternary kinase, eIF4G. Moreover, these data offer an explanation of the molecular mechanism by which amino acids modulate myogenic growth, via activation of the hVps34 protein. Finally, while exogenous leucine and insulin were sufficient to stimulate anabolic signalling in cultured myotubes, incubation did not alter gene expression of the amino acid transporters measured.

The use of human primary myotubes provides pertinent experimental data on amino acid-mediated anabolic signalling that occurs in human skeletal muscle tissue. Cultured muscle cells undergo differentiation to form mature myotubes [37] thus providing a physiologically relevant model to study molecular signalling events which occur in vivo. In agreement with data from rodent studies [17, 14, 9, 20], Chinese hamster ovary cells (CHO) [38], pancreatic beta-cells [39] and rat hepatocytes [40], this study demonstrates for the first time that mTOR-related signalling kinases are responsive to a physiological dose of leucine in a human model of skeletal muscle, primary myotubes. However, while mTOR was stimulated by insulin on serine residue 2448, at all time points measured, the action of leucine was transient (1.3-fold increase) with phosphorylation diminishing after 30 min. This is consistent with Deldicque et al. (2008) who demonstrated a 1.5-fold increase in mTOR activation within C2C12 cells, a model of murine skeletal muscle, following an acute 30 min exposure to 5 mM leucine [17]. However, more recently it was reported that a 2 mM dose of leucine also stimulates mTOR phosphorylation on Ser2448 by a comparable magnitude [14]. The downstream biomarker, p70S6K, followed a similar trend to mTOR phosphorylation. While leucine demonstrated transient activation of p70S6K (2.0-fold increase), insulin appeared to stimulate this kinase at all time points. Previous work has demonstrated that 5 mM leucine stimulates p70S6K activation by 10-fold [17] and a 2 mM dose elicits a 5.9-fold increase [14] within rodent muscle cells. Furthermore, cultured pancreatic beta-cells have been shown to respond to 3.3 mM of leucine, therefore the stimulatory effect of leucine on the phosphorylation state of p70S6K may be specific to the cell model employed where by different cell types have a varying dose-response to amino acids [39]. Previous in vitro experiments demonstrates the synergistic activation of p70S6K in FAO cells treated with a combination of amino acids with insulin [41]. Results obtained from the current study did not exhibit an additive effect of leucine and insulin, despite utilising the same insulin concentration. While these experiments were conducted using leucine only, the former study used a mixture of amino acids. Furthermore, recent evidence suggests that while the activation of anabolic signalling is indeed mTOR-dependent, amino acids may signal through the Rag complex to activate mTORC1 while insulin requires the Ras homolog enriched in brain (Rheb) component to regulate anabolic signalling [42]. Moreover, it has also been previously shown that deletion of the Ser2448 phosphorylation site on mTOR did not affect mTOR activity and was not required for the downstream phosphorylation of PHAS-1 (4EBP1) or p70S6K in human embryonic kidney cells [43]. Therefore, it is possible that while mTOR phosphorylation in this study was transient, the downstream activation of p70S6K and eIF4G may occur through an independent signalling mechanism and requires further research.

Surprisingly, phosphorylation of eIF4G occurred following 3 h and 24 h treatment of leucine and insulin. Given that activation of eIF4G is a necessary step during formation of the translation initiation complex which is involved in cap dependent translation [13, 44], activation by leucine indicates that protein synthesis may be initiated without insulin.

hVps34 is postulated to be a nutrient modulator responsible for signalling to mTOR. Recently, amino acid regulation of this class III PI3 kinase has been investigated in murine myotubes [28], HepG2 and CHO cells [29]. During states of amino acid starvation, hVps34 demonstrates reduced function. However, this is restored with the re-addition of amino acids [27, 29]. Furthermore, previous reports demonstrate that endogenous expression of hVps34 is unresponsive to 1 μM insulin [29]. Unlike these studies, human primary muscle cells demonstrated increased hVps34 protein abundance following acute and chronic stimulation of leucine with and without 100 nM insulin. The response of hVps34 to insulin in cultured myotubes may reflect the physiological need of skeletal muscle for insulin-mediated glucose uptake and for muscle anabolism [45, 46]. Limited studies have investigated the factors regulating hVps34 expression; however the possibility of cross-talk with insulin signalling requires further analysis.

Both system A and L solute carriers may regulate intracellular amino acid bioavailability within skeletal muscle [47]. The activity of system A transporters has been previously demonstrated to be insulin responsive cultured adipocytes, liver and rat muscle cells [48–50].

However, in cultured human myotubes both acute and chronic stimulation with insulin failed to increase SNAT2 and LAT1 gene expression. It is important to note that the aforementioned studies used supraphysiological doses of insulin, nearly 2-fold greater than the concentration used in the current study. System L transport proteins are essential for the movement of BCAA across the cell membrane of skeletal muscle cells [47]. Leucine exposure of human cultured primary muscle cells did not exert a change in either LAT1 or LAT4 gene expression, despite the specificity of LAT1 for leucine [51]. However, functional expression of LAT1 requires covalent association with the heavy chain of the CD98 antigen (CD98hc) in plasma membranes [52]. Acute insulin exposure stimulated an increase in CD98hc mRNA expression, however longer exposure resulted in suppressed gene expression. The current study aimed to present exploratory data on the regulation of amino acid transporters by leucine. Given the physiological need for amino acids in skeletal muscle, further research is required to delineate the factors affecting both the protein expression and cellular localisation of amino acid transporters.

Conclusions

The present study provides the first evidence that mTOR signalling is enhanced in response to an acute stimulation with the proteinogenic amino acid, leucine, within cultured human myotubes. While these actions appear transient at the leucine dose utilised, activation of mTOR and p70S6K occurred at physiologically relevant concentrations independently of insulin stimulation. Interestingly, activation of mTOR signalling by leucine occurred in the absence of changes in the expression of genes encoding both the system A and system L carriers, which are responsible for amino acid transport. Thus, additional analyses are required to investigate the molecular mechanisms controlling amino acid transporter expression within skeletal muscle. Of note was the increased protein expression of hVps34, a putative leucine-sensitive kinase which intersects with mTOR. These results demonstrate the need for further clinical analysis to be performed specifically investigating the role of hVps34 as a nutrient sensing protein for mTOR signalling.

Methods

Subjects

Human primary skeletal muscle cells were obtained from the vastus lateralis muscle of six healthy male volunteers (24.6 ± 0.4 years). Informed written consent was obtained from each subject before participation in the study, after the nature, purpose and risks of the study were explained. All experimental procedures involved in this study were formally approved by the Deakin University Ethics Committee.

Primary human skeletal muscle cell culture

Human primary skeletal muscle cells were cultured as previously described [53] using the percutaneous needle biopsy technique [37] modified to include suction [54]. The excised muscle was immersed and extensively washed in ice-cold Ham's F-10 medium (Gibco, Invitrogen Corporation, California, USA) containing 50 IU/ml penicillin, and 5 μg/ml streptomycin before being minced and digested in 0.5% Trypsin/EDTA (Gibco). The supernatant containing the myoblasts was then collected and the process repeated a further two times to break down any remaining tissue. Foetal bovine serum (FBS) (Gibco) was subsequently added to the supernatant to a final concentration of 10% (v/v). The supernatant was filtered through a 100 μm filter to remove any connective tissue and then spun to collect the cells. The resulting cell pellet was resuspended in primary growth medium (Hams F-10, 10% FBS, with 50 IU/mL penicillin, 5 μg/mL streptomycin and 2.5 pg/mL fibroblast growth factor-2 (FGF-2; Promega, Wisconsin, USA)) and then seeded on to an uncoated flask and incubated at 37°C for 30 minutes to induce fibroblast attachment, leaving myoblasts suspended in the medium. The medium was then transferred to second uncoated flask for a further 30 min to allow for any additional fibroblast attachment. The medium was aspirated and seeded on to an extracellular matrix-coated (ECM) (Sigma-Aldrich, New South Wales, Australia) flask. The resulting primary cell cultures were maintained in primary growth medium in humidified air at 37°C containing 5% CO2. To determine culture homogeneity, the expression of specific myogenic markers (myoD, myogenin and desmin) was analysed using immunocytochemistry (Figure 1). In all experiments, the minimal myogenic purity was 80% for myoblast preparations [55].

Leucine and insulin stimulation experiments

When cells reached 70% confluence, proliferation medium was replaced with differentiation medium containing 2% horse serum. Following 7 d of differentiation, cells were serum starved overnight (16 h) prior to treatment. Myotubes were then exposed to serum-free media containing an additional 5 mM of water-soluble L-leucine (Calbiochem, California, USA) ± human insulin (100 nM; Actrapid®; Novo Nordisk, Australia) for either 30 min, 3 h or 24 h. Five millimolar was selected as an appropriate concentration for these experiments as dose-response studies demonstrated that 5 mM L-leucine achieved the greatest stimulatory effect (data not shown). All experiments were conducted on cells at passage five.

Protein extraction and immunoblot analysis of insulin signalling kinases

Cells were lysed after 30 min, 3 h and 24 h, in lysis buffer (pH 7.0) containing 20 mM Tris-HCl, 5 mM EDTA, 10 mM Na-pyrophosphate, 100 mM NaF, 2 mM Na3VO4, 1% Igepal, 10 μg/mL Aprotinin, 10 μg/mL Leupeptin, 3 mM Benzamidine and 1 mM PMSF. The supernatants were rotated for 1 h at 4°C and subsequently centrifuged at 14,000 rpm for 15 min with the resulting supernatant collected into a fresh tube. Protein concentrations were determined using a BCA Protein Assay (Pierce, Thermo Scientific, New South Wales, Australia) with bovine serum albumin (BSA) as standard.

Protein lysates were denatured in loading buffer containing dithiothreitol (DTT) and separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were then transferred onto nitrocellulose membrane and blocked at room temperature using 5% (w/v) BSA (Sigma-Aldrich) in tris buffered saline with 0.1% (v/v) Tween-20 (TBST; Sigma-Aldrich). The following phospho-specific antibodies were added and incubated overnight at 4°C in blocking buffer: mTORSer2448, p70S6KThr389, eIF4GSer1108 (Cell Signaling, Massachusetts, USA) and hVps34 (Santa Cruz). Membranes were subsequently washed and then incubated with anti-rabbit HRP-conjugated secondary antibody (1:1000; Calbiochem) for 1 h at room temperature. Following this, membranes were washed repeatedly as before, and proteins visualised using enhanced chemiluminescence (Perkin-Elmer, Queensland, Australia) on a Kodak 4000MM Image Station (Kodak, New York, USA) using a CCD camera. Band density was quantified using Kodak imaging software version 4.5.0 (Kodak). For normalisation, blots were stripped using Restore Western Blot Stripping buffer™ (Quantum Scientific, Victoria, Australia) and then subsequently reprobed for total mTOR, total p70S6K and total eIF4G proteins to verify the relative amount of analysed proteins.

RNA extraction

RNA was extracted from primary myotubes using TRI-reagent (Ambion Inc., Texas, USA) after the treatment period. Chloroform was added to separate phases. Following centrifugation for 15 min at 14,000 rpm, the aqueous layer was removed and an equal volume of isopropanol added and incubated at -20°C for 1 h. Following RNA precipitation, samples were centrifuged at 14,000 rpm to pellet the RNA. The pellet was washed with 75% ethanol in diethyl pyrocarbonate (DEPC)-treated water and then resuspended in nuclease free water (NFW). Total RNA concentration and quality were determined using the Nanodrop ND-1000 (Nanodrop Technologies, Delaware, USA).

cDNA synthesis

First strand cDNA was generated from 1 μg total RNA using the High Capacity RNA-to-cDNA kit (Applied Biosystems) according to manufacturer's instructions. Briefly, a 20 μL reaction mixture consisting of 1 μg of total RNA, 10 μL of 2X RT Buffer Reaction Mix, 1 μL of 20X RT Enzyme Mix and a known amount of NFW and placed into the thermocycler (Hybaid, Thermo Scientific) with the following temperature and time protocol: 37°C for 60 min, 95°C for 5 min, and 4°C for 5 min. All synthesised cDNA samples were stored at -20°C until further analysis.

Semi-quantitative real time PCR (qPCR)

Analysis of gene expression was performed using the Applied Biosystems 7500 Real-Time PCR system (Applied Biosystems). cDNA (diluted 1:20) was analysed using SYBR green fluorescence (Power SYBR Green Master Mix, Applied Biosystems) and with primer pairs specific for the gene of interest. Oligonucleotide primers were designed using Primer Express 3.0 (Applied Biosystems) software and validated using BLAST sequence alignment and in the absence of primer-dimers and secondary structures. All oligonucleotides were purchased from Geneworks (South Australia, Australia). Refer to Table 1 for primer sequences.

Table 1 Details of primer sequences used in qPCR analysis
Full size table

Each reaction contained 8 μL of 2X Sybr green master mix, 2 μL of forward primer, 2 μL of reverse primer, 6 μL sterile nuclease-free water and 2 μL of cDNA (1.25 ng/μL). All samples were run in triplicate. An initial cycle of 10 min at 95°C was used to denature the cDNA, followed by 40 cycles consisting of 95°C for 15 s and subsequent extension at 60°C for 1 min.

Reference gene normalisation and calculations

Data were analysed using comparative critical threshold (Ct) method where the amount of target normalised to the amount of endogenous control is given by 2-≠≠Ct (Applied Biosystems). The efficacy of cyclophilin (CYC) as an endogenous control was examined using the equation 2-≠Ct. It was considered an appropriate endogenous control for this study because no changes in the expression of this gene were observed (data not shown).

Statistical analysis

Statistical analysis was performed using SPSS version 17.0 for Windows (SPSS Inc., Illinois, USA). Data are reported as means ± standard error of the mean (SEM). All data sets were tested for normal distribution and variance homogeneity using Levene's test for Equality of Variances. A Student's t-test was used to determine significance between the treatment groups. A probability level of <0.05 was adopted throughout to determine statistical significance unless otherwise stated.

Abbreviations

BCAA:

branched-chain amino acid

hVps34:

human vacuolar protein sorting 34

LAT:

L-type amino acid transporter

mTOR:

mammalian target of rapamycin

mRNA:

messenger RNA

p70S6K:

p70 ribosomal S6 kinase

SNAT2:

sodium coupled neutral amino acid transporter 2

References

  1. 1.

    Nelsen CJ, Rickheim DG, Tucker MM, Hansen LK, Albrecht JH: Evidence that cyclin D1 mediates both growth and proliferation downstream of TOR in hepatocytes. J Biol Chem. 2003, 278: 3656-3663. 10.1074/jbc.M209374200.

  2. 2.

    Nelsen CJ, Rickheim DG, Tucker MM, McKenzie TJ, Hansen LK, Pestell RG, Albrecht JH: Amino acids regulate hepatocyte proliferation through modulation of cyclin D1 expression. J Biol Chem. 2003, 278: 25853-25858. 10.1074/jbc.M302360200.

  3. 3.

    Buse MG, Reid SS: Leucine. A possible regulator of protein turnover in muscle. J Clin Invest. 1975, 56: 1250-1261. 10.1172/JCI108201.

  4. 4.

    Fujita S, Dreyer HC, Drummond MJ, Glynn EL, Volpi E, Rasmussen BB: Essential amino acid and carbohydrate ingestion before resistance exercise does not enhance postexercise muscle protein synthesis. J Appl Physiol. 2009, 106: 1730-1739. 10.1152/japplphysiol.90395.2008.

  5. 5.

    Cuthbertson D, Smith K, Babraj J, Leese G, Waddell T, Atherton P, Wackerhage H, Taylor PM, Rennie MJ: Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle. Faseb J. 2005, 19: 422-424.

  6. 6.

    Atherton PJ, Etheridge T, Watt PW, Wilkinson D, Selby A, Rankin D, Smith K, Rennie MJ: Muscle full effect after oral protein: time-dependent concordance and discordance between human muscle protein synthesis and mTORC1 signaling. Am J Clin Nutr. 2010

  7. 7.

    Greiwe JS, Kwon G, McDaniel ML, Semenkovich CF: Leucine and insulin activate p70 S6 kinase through different pathways in human skeletal muscle. Am J Physiol Endocrinol Metab. 2001, 281: E466-471.

  8. 8.

    Liu Z, Jahn LA, Wei L, Long W, Barrett EJ: Amino acids stimulate translation initiation and protein synthesis through an Akt-independent pathway in human skeletal muscle. J Clin Endocrinol Metab. 2002, 87: 5553-5558. 10.1210/jc.2002-020424.

  9. 9.

    Kimball SR, Shantz LM, Horetsky RL, Jefferson LS: Leucine Regulates Translation of Specific mRNAs in L6 Myoblasts through mTOR-mediated Changes in Availability of eIF4E and Phosphorylation of Ribosomal Protein S6. J Biol Chem. 1999, 274: 11647-11652. 10.1074/jbc.274.17.11647.

  10. 10.

    Anthony JC, Anthony TG, Kimball SR, Jefferson LS: Signaling pathways involved in translational control of protein synthesis in skeletal muscle by leucine. J Nutr. 2001, 131: 856S-860S.

  11. 11.

    Hara K, Maruki Y, Long X, Yoshino K-i, Oshiro N, Hidayat S, Tokunaga C, Avruch J, Yonezawa K: Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action. Cell. 2002, 110: 177-189. 10.1016/S0092-8674(02)00833-4.

  12. 12.

    Avruch J, Belham C, Weng Q, Hara K, Yonezawa K: The p70 S6 kinase integrates nutrient and growth signals to control translational capacity. Prog Mol Subcell Biol. 2001, 26: 115-154.

  13. 13.

    Kozak M, Shatkin AJ: Identification of features in 5' terminal fragments from reovirus mRNA which are important for ribosome binding. Cell. 1978, 13: 201-212. 10.1016/0092-8674(78)90150-2.

  14. 14.

    Atherton PJ, Smith K, Etheridge T, Rankin D, Rennie MJ: Distinct anabolic signalling responses to amino acids in C2C12 skeletal muscle cells. Amino Acids. 2010, 38: 1533-1539. 10.1007/s00726-009-0377-x.

  15. 15.

    Dreyer HC, Drummond MJ, Pennings B, Fujita S, Glynn EL, Chinkes DL, Dhanani S, Volpi E, Rasmussen BB: Leucine-enriched essential amino acid and carbohydrate ingestion following resistance exercise enhances mTOR signaling and protein synthesis in human muscle. Am J Physiol Endocrinol Metab. 2008, 294: E392-400.

  16. 16.

    Drummond MJ, Rasmussen BB: Leucine-enriched nutrients and the regulation of mammalian target of rapamycin signalling and human skeletal muscle protein synthesis. Curr Opin Clin Nutr Metab Care. 2008, 11: 222-226. 10.1097/MCO.0b013e3282fa17fb.

  17. 17.

    Deldicque L, Sanchez Canedo C, Horman S, De Potter I, Bertrand L, Hue L, Francaux M: Antagonistic effects of leucine and glutamine on the mTOR pathway in myogenic C2C12 cells. Amino Acids. 2008, 35: 147-155. 10.1007/s00726-007-0607-z.

  18. 18.

    Glynn E, Fry C, Drummond M, Timmerman K, Dhanani S, Volpi E, Rasmussen B: Excess leucine intake enhances muscle anabolic signaling but not net protein anabolism in young men and women. J Nutr. 2010, 140: 1970-1976. 10.3945/jn.110.127647.

  19. 19.

    Ishizuka Y, Kakiya N, Nawa H, Takei N: Leucine induces phosphorylation and activation of p70S6K in cortical neurons via the system L amino acid transporter. J Neurochem. 2008, 106: 934-942. 10.1111/j.1471-4159.2008.05438.x.

  20. 20.

    Kimball SR, Shantz LM, Horetsky RL, Jefferson LS: Leucine regulates translation of specific mRNAs in L6 myoblasts through mTOR-mediated changes in availability of eIF4E and phosphorylation of ribosomal protein S6. J Biol Chem. 1999, 274: 11647-11652. 10.1074/jbc.274.17.11647.

  21. 21.

    Norton LE, Layman DK, Bunpo P, Anthony TG, Brana DV, Garlick PJ: The leucine content of a complete meal directs peak activation but not duration of skeletal muscle protein synthesis and mammalian target of rapamycin signaling in rats. J Nutr. 2009, 139: 1103-1109. 10.3945/jn.108.103853.

  22. 22.

    Shah OJ, Antonetti DA, Kimball SR, Jefferson LS: Leucine, glutamine, and tyrosine reciprocally modulate the translation initiation factors eIF4F and eIF2B in perfused rat liver. J Biol Chem. 1999, 274: 36168-36175. 10.1074/jbc.274.51.36168.

  23. 23.

    Iraqui I, Vissers S, Bernard F, de Craene JO, Boles E, Urrestarazu A, Andre B: Amino acid signaling in Saccharomyces cerevisiae: a permease-like sensor of external amino acids and F-Box protein Grr1p are required for transcriptional induction of the AGP1 gene, which encodes a broad-specificity amino acid permease. Mol Cell Biol. 1999, 19: 989-1001.

  24. 24.

    Ferenci T: Regulation by nutrient limitation. Curr Opin Microbiol. 1999, 2: 208-213. 10.1016/S1369-5274(99)80036-8.

  25. 25.

    Findlay GM, Yan L, Procter J, Mieulet V, Lamb RF: A MAP4 kinase related to Ste20 is a nutrient-sensitive regulator of mTOR signalling. Biochem J. 2007, 403: 13-20. 10.1042/BJ20061881.

  26. 26.

    Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-Peled L, Sabatini DM: The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science. 2008, 320: 1496-1501. 10.1126/science.1157535.

  27. 27.

    Nobukuni T, Joaquin M, Roccio M, Dann SG, Kim SY, Gulati P, Byfield MP, Backer J, Matt F, Bos JL, Zwartkruis FJ, Thomas G: Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc Natl Acad Sci USA. 2005, 102: 14238-14243. 10.1073/pnas.0506925102.

  28. 28.

    MacKenzie MG, Hamilton DL, Murray JT, Taylor PM, Baar K: mVps34 is activated following high-resistance contractions. J Physiol. 2009, 587: 253-260. 10.1113/jphysiol.2008.159830.

  29. 29.

    Byfield MP, Murray JT, Backer JM: hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. J Biol Chem. 2005, 280: 33076-33082. 10.1074/jbc.M507201200.

  30. 30.

    Bodoy S, Martin L, Zorzano A, Palacin M, Estevez R, Bertran J: Identification of LAT4, a novel amino acid transporter with system L activity. J Biol Chem. 2005, 280: 12002-12011. 10.1074/jbc.M408638200.

  31. 31.

    Riggs TR, McKirahan KJ: Action of insulin on transport of L-alanine into rat diaphragm in vitro. Evidence that the hormone affects only one neutral amino acid transport system. J Biol Chem. 1973, 248: 6450-6455.

  32. 32.

    Zorzano A, Balon TW, Goodman MN, Ruderman NB: Insulin and exercise stimulate muscle alpha-aminoisobutyric acid transport by a Na+-K+-ATPase independent pathway. Biochem Biophys Res Commun. 1986, 134: 1342-1349. 10.1016/0006-291X(86)90397-9.

  33. 33.

    Kashiwagi H, Yamazaki K, Takekuma Y, Ganapathy V, Sugawara M: Regulatory mechanisms of SNAT2, an amino acid transporter, in L6 rat skeletal muscle cells by insulin, osmotic shock and amino acid deprivation. Amino Acids. 2008

  34. 34.

    McDowell HE, Christie GR, Stenhouse G, Hundal HS: Leucine activates system A amino acid transport in L6 rat skeletal muscle cells. Am J Physiol. 1995, 269: C1287-1294.

  35. 35.

    Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T, Cha SH, Matsuo H, Fukushima J, Fukasawa Y, Tani Y, Taketani Y, Uchino H, Kim JY, Inatomi J, Okayasu I, Miyamoto K, Takeda E, Goya T, Endou H: Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta. 2001, 1514: 291-302. 10.1016/S0005-2736(01)00384-4.

  36. 36.

    Kobayashi K, Ohnishi A, Promsuk J, Shimizu S, Kanai Y, Shiokawa Y, Nagane M: Enhanced tumor growth elicited by L-type amino acid transporter 1 in human malignant glioma cells. Neurosurgery. 2008, 62: 493-503. 10.1227/01.neu.0000316018.51292.19. discussion 503-494

  37. 37.

    Gaster M, Kristensen SR, Beck-Nielsen H, Schroder HD: A cellular model system of differentiated human myotubes. APMIS. 2001, 109: 735-744. 10.1034/j.1600-0463.2001.d01-140.x.

  38. 38.

    Wang X, Campbell LE, Miller CM, Proud CG: Amino acid availability regulates p70 S6 kinase and multiple translation factors. Biochem J. 1998, 334 (Pt 1): 261-267.

  39. 39.

    Xu G, Kwon G, Marshall CA, Lin TA, Lawrence JC, McDaniel ML: Branched-chain amino acids are essential in the regulation of PHAS-I and p70 S6 kinase by pancreatic beta-cells. A possible role in protein translation and mitogenic signaling. J Biol Chem. 1998, 273: 28178-28184. 10.1074/jbc.273.43.28178.

  40. 40.

    Krause U, Bertrand L, Maisin L, Rosa M, Hue L: Signalling pathways and combinatory effects of insulin and amino acids in isolated rat hepatocytes. Eur J Biochem. 2002, 269: 3742-3750. 10.1046/j.1432-1033.2002.03069.x.

  41. 41.

    Patti ME, Brambilla E, Luzi L, Landaker EJ, Kahn CR: Bidirectional modulation of insulin action by amino acids. J Clin Invest. 1998, 101: 1519-1529. 10.1172/JCI1326.

  42. 42.

    Dennis MD, Baum JI, Kimball SR, Jefferson LS: Mechanisms involved in the coordinate regulation of mTORC1 by insulin and amino acids. J Biol Chem. 2011, 286: 8287-8296. 10.1074/jbc.M110.209171.

  43. 43.

    Sekulic A, Hudson CC, Homme JL, Yin P, Otterness DM, Karnitz LM, Abraham RT: A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 2000, 60: 3504-3513.

  44. 44.

    Bolster DR, Vary TC, Kimball SR, Jefferson LS: Leucine regulates translation initiation in rat skeletal muscle via enhanced eIF4G phosphorylation. J Nutr. 2004, 134: 1704-1710.

  45. 45.

    Hillier T, Long W, Jahn L, Wei L, Barrett EJ: Physiological hyperinsulinemia stimulates p70(S6k) phosphorylation in human skeletal muscle. J Clin Endocrinol Metab. 2000, 85: 4900-4904. 10.1210/jc.85.12.4900.

  46. 46.

    Kimball SR, Vary TC, Jefferson LS: Regulation of protein synthesis by insulin. Annu Rev Physiol. 1994, 56: 321-348. 10.1146/annurev.ph.56.030194.001541.

  47. 47.

    McGivan JD, Pastor-Anglada M: Regulatory and molecular aspects of mammalian amino acid transport. Biochem J. 1994, 299 (Pt 2): 321-334.

  48. 48.

    Kashiwagi H, Yamazaki K, Takekuma Y, Ganapathy V, Sugawara M: Regulatory mechanisms of SNAT2, an amino acid transporter, in L6 rat skeletal muscle cells by insulin, osmotic shock and amino acid deprivation. Amino Acids. 2009, 36: 219-230. 10.1007/s00726-008-0050-9.

  49. 49.

    Kletzien RF, Pariza MW, Becker JE, Potter VR, Butcher FR: Induction of amino acid transport in primary cultures of adult rat liver parenchymal cells by insulin. J Biol Chem. 1976, 251: 3014-3020.

  50. 50.

    Su TZ, Wang M, Syu LJ, Saltiel AR, Oxender DL: Regulation of system A amino acid transport in 3T3-L1 adipocytes by insulin. J Biol Chem. 1998, 273: 3173-3179. 10.1074/jbc.273.6.3173.

  51. 51.

    Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H: Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem. 1998, 273: 23629-23632. 10.1074/jbc.273.37.23629.

  52. 52.

    Segawa H, Fukasawa Y, Miyamoto K, Takeda E, Endou H, Kanai Y: Identification and functional characterization of a Na+-independent neutral amino acid transporter with broad substrate selectivity. J Biol Chem. 1999, 274: 19745-19751. 10.1074/jbc.274.28.19745.

  53. 53.

    Caldow MK, Steinberg GR, Cameron-Smith D: Impact of SOCS3 overexpression on human skeletal muscle development in vitro. Cytokine. In Press, Corrected Proof

  54. 54.

    Evans WJ, Phinney SD, Young VR: Suction applied to a muscle biopsy maximizes sample size. Med Sci Sports Exerc. 1982, 14: 101-102.

  55. 55.

    Rando TA, Blau HM: Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy. J Cell Biol. 1994, 125: 1275-1287. 10.1083/jcb.125.6.1275.

Download references

Acknowledgements

We thank Dr Andrew Garnham (Deakin University) for all muscle biopsy procedures, and the participants for volunteering for a resting muscle biopsy. The authors also thank Dr Marissa Caldow for her assistance in the preparation of this manuscript. This research was supported by a PhD scholarship from the Dairy Health and Nutrition Consortium held by PG.

Author information

Affiliations

  1. Molecular Nutrition Unit, School of Exercise and Nutrition Sciences, Deakin University, Burwood, Victoria, Australia

    • Petra Gran
    •  & David Cameron-Smith

Authors

  1. Search for Petra Gran in:

  2. Search for David Cameron-Smith in:

Corresponding author

Correspondence to David Cameron-Smith.

Additional information

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

PG conducted all experiments, statistical analyses and drafted the manuscript. DCS conceived the study, participated in its design and coordination and helped to draft the manuscript. Both authors read and approved the final manuscript.

Electronic supplementary material

Additional file 1:Protein abundance of total mTOR is not affected by either leucine or insulin. A figure representing the protein expression of total mTOR at 30 min, 3 h and 24 h. Primary human myotubes were untreated or incubated in the presence of leucine (Leu; 5 mM), insulin (Ins; 100 nM) or co-treated with leucine and insulin (Leu + Ins) for 30 min (A), 3 h (B) or 24 h (C). Protein abundance of total mTOR was determined by Western blot analysis. Data are presented as mean ± SEM (n = 6). (JPEG 547 KB)

Authors’ original submitted files for images

Below are the links to the authors’ original submitted files for images.

Authors’ original file for figure 1

Authors’ original file for figure 2

Authors’ original file for figure 3

Authors’ original file for figure 4

Authors’ original file for figure 5

Authors’ original file for figure 6

Authors’ original file for figure 7

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Keywords

  • Amino Acid Transporter
  • Branch Chain Amino Acid
  • mTOR Signalling
  • Insulin Stimulation
  • mTOR Phosphorylation

BMC Physiology

ISSN: 1472-6793